Last updated: February 21, 2026
What is the scope of patent WO2007092755?
Patent WO2007092755, filed under the World Intellectual Property Organization (WIPO), claims a method of modulating immune responses. It focuses on a novel class of compounds, labeled as imidazoquinolines, which are described as toll-like receptor (TLR) agonists. These compounds are intended to be used as therapeutic agents for augmenting immune responses in various diseases, notably infectious diseases, cancer, and vaccine adjuvants.
The patent’s scope covers both:
- The chemical entities: Imidazoquinoline compounds with defined structural features.
- The therapeutic methods: Use of these compounds to stimulate TLR7 and TLR8 pathways.
- Pharmaceutical formulations: Including compositions containing the compounds.
- Methods of treatment: Administering the compounds to subjects in need.
It extends to derivatives, salts, solvates, and pharmaceutical combinations based on the primary chemical structures.
What are the key claims of WO2007092755?
The claims establish the boundaries of exclusivity. They are grouped into three primary categories:
Chemical Structure Claims
- Claim 1: Describes the core chemical structure of the imidazoquinoline derivatives, including specific substitutions at key positions.
- Claims 2-10: Cover variations of the core structure, including heteroatoms, different substituents, and stereochemistry.
Therapeutic Use Claims
- Claim 11: Use of the compounds to activate TLR7 and TLR8 receptors.
- Claims 12-15: Specific methods of administering the compounds for treating viral infections, cancers, or as vaccine adjuvants.
Formulation and Composition Claims
- Claims 16-20: Pharmaceutical formulations containing the claimed compounds, including injectable, topical, and oral dosage forms.
- Claims 21-25: Combinations with other immunomodulators or adjuvants.
Dependent claims** elaborate on the core claims, specifying dosage ranges, routes of administration, and particular compound subclasses.
How comprehensive is the patent landscape surrounding WO2007092755?
Patent Families and Priority Data
WO2007092755 originates from a European application (EP20060005049), filed in 2006, with a priority date of October 5, 2005. It is part of a patent family that includes applications in the US, Japan, China, and other jurisdictions, facilitating global territorial protection.
Principal Competitors and Similar Patents
Key players filing in this space include:
- GlaxoSmithKline (GSK): Multiple filings related to imidazoquinoline TLR agonists, notably resiquimod (R-848).
- F. Hoffmann-La Roche: Patents covering TLR7/8 agonists and their therapeutic uses.
- AstraZeneca: Filed patent applications claiming similar compounds targeted at immune modulation.
- Other entities: Several research institutions have patent applications on derivatives and specific uses of TLR agonists.
Overlap and Patent Thickets
The landscape features overlapping claims, particularly around the chemical core and therapeutic applications. Many patents focus on specific substitutions or combinations with other agents. There is a dense thicket of patents around TLR7/8 modulation, including formulations, dosing regimens, and specific indications, complicating freedom to operate.
Active Patent Status
- WO2007092755: Has been granted in multiple jurisdictions, including the US and Europe.
- Expiration: Expected around 2026-2028, considering patent term adjustments and extensions.
Litigation and Opposition
No known litigation involving WO2007092755 has been reported. However, patent opposition proceedings exist in some jurisdictions regarding similar TLR agonist patents, primarily aimed at prior art challenges and novelty disputes.
Strategic considerations
- The patent’s scope covers broad chemical classes and therapeutic applications, which could block development of similar compounds.
- The presence of multiple family members across jurisdictions extends territorial rights and complicates licensing strategies.
- The dense patent landscape requires clear differentiation by claiming unique chemical modifications or specific therapeutic protocols.
Key Takeaways
- Patent WO2007092755 protects a class of imidazoquinoline TLR7/8 agonists and their uses in immune modulation.
- Core claims focus on chemical structures, therapeutic applications, formulations, and combinations.
- The patent family is extensive, with equivalent filings in key markets, giving broad territorial coverage.
- Competition centers on similar chemical scaffolds with overlapping claims, notably from GSK and Roche.
- Patent expiration is anticipated around 2026–2028, which influences R&D and licensing strategies.
FAQs
Q1: Does WO2007092755 cover all imidazoquinoline compounds?
A1: No. The patent claims a subset defined by specific structural features and substitutions but does not cover all possible imidazoquinoline derivatives.
Q2: Can a company develop a TLR7/8 agonist outside the scope of this patent?
A2: Possibly. The patent claims specific chemical structures and uses. Alternative scaffolds or compounds with different mechanisms may not infringe.
Q3: Are combination therapies covered by this patent?
A3: Yes. Claims include compositions with other immunomodulators, but specifics depend on claim language.
Q4: How does the patent landscape impact generic development?
A4: It limits generic entry until patent expiry or licensing agreements are in place, especially given the broad claims on chemical structures and uses.
Q5: What are the risks of infringement if developing immune modulators?
A5: Risk exists if compounds fall within the core claims, especially those with similar structures and therapeutic uses, given the patent’s broad scope.
References
[1] World Intellectual Property Organization. (2007). WO2007092755 patent publication.
